Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00385203
Status:
COMPLETED
Last Update Posted:
2012-07-16
First Post:
2006-10-05
Brief Title:
The Biological Activity of Cediranib AZD2171 in Gastro-Intestinal Stromal TumoursGIST
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An Open-Label Phase II Study to Evaluate the Biological Activity of Cediranib AZD2171 as Measured by F 18 Fluoro 2 Deoxy D Glucose - Positron Emission Tomography FDG-PET Response in Patients With Metastatic Gastro-Intestinal Stromal Tumours GIST Resistant or Intolerant to Imatinib Mesylate
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the anti-tumour activity and biological effects of cediranib AZD2171 at a dose of 45mg primarily in Gastrointestinal Stromal Tumour GIST patients who are resistant to imatinib mesylate current standard therapy and also in patients with metastatic Soft Tissue Sarcoma STS resistant to standard therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None